H&Q Life Sciences Investors (""HQL"") is a broadly diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQL. HQL primarily invests in the life sciences (including biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies, agriculture and environmental management industries). The Fund's objective is to provide long-term capital appreciation through investments in companies in the life sciences industries believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.
Contact Investor Relations
H&Q Life Sciences Investors Investor Relations 2 Liberty Square Boston, MA 02109 United States Phone: 1.617.772.8500 SIC Code:6726
Daniel R. Omstead, Ph.D., President and Chief Executive Officer
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Christopher F. Brinzey, Senior Vice President, Research
Chris Brinzey joined TCM in February of 2001 and is responsible for investment research and venture investment due diligence in the following areas: specialty pharmaceuticals and healthcare information technology and services. Prior to joining TCM, Chris was a senior analyst for Advest Incorporated's healthcare research team where he covered and helped to finance a number of companies in the healthcare information technology and eHealth sector. Other prior work experience includes project management and consulting for SunGard Financial Systems, a subsidiary of SunGard da Systems, a global IT solutions and eProcessing company. Chris received a B.A. in psychology from Hobart College and an MBA from Northeastern University.
Frank T. Gentile Ph.D., Senior Vice President, Research
Dr. Frank T. Gentile joined TCM in September 2002 as Vice President, Research; His emphasis is on the analysis of private and public companies in the fields of Functional Genomics and Proteomics, Cell and Gene Therapy, Oncology and Cardiovascular Disease. Previously Frank was Vice President, Technology Program Management at Millennium Pharmaceuticals. At Millennium, Frank was responsible for management of all technology platform development programs. Prior to joining Millennium, Frank was Vice President of Product Development at Curis, Inc., a biotechnology company in Cambridge developing products in the area of Regenerative Medicine. From 1997 to 2000 he was Director and then Vice President, Program Management at Reprogenesis, Inc. From 1990-1997 he was employed at CytoTherapeutics, Inc, where he held several scientific and management positions. Frank received a B.E. degree in Chemical Engineering from The Cooper Union and a Ph.D. in Chemical Engineering from MIT. Prior to working in industry, he was a post-doctoral fellow at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland. He is also an Adjunct Associate Professor of Biotechnology at Brown University. He has written over 120 peer reviewed publications and holds 30 US patents in the area of biotechnology.
Jason C. Akus, MD, Vice President, Research
Jason Akus is responsible for investment research and due diligence in the Medical Device, Diagnostic, and Biopharmaceutical areas. Jason joined TCM in July of 2001 after graduating from Tufts with an M.D. and M.B.A. Jason graduated from Tufts with a B.S. in Mathematics. During medical school, Jason consulted for a variety of Healthcare IT companies.
Peter Savitscus, Head of Trading
Peter Savitscus joined TCM in April 2005 as Head Trader. Peter is responsible for trading operations and technical research of potential and existing portfolio securities. Peter has over nine years of equity trading experience. Peter previously worked as Proprietary Trader with Fair Haven Capital, LLC. Peter graduated with a B.A. from Villanova University.
Laura Woodward, Chief Compliance Officer and Vice President of Fund Administrati
Laura Woodward joined TCM in May 2009 as Chief Compliance Officer and Vice President of Fund Administration. Laura is also Secretary and Treasurer of the Funds. Previously, Laura was a Senior Manager with PricewaterhouseCoopers LLP. Laura is responsible for providing support for and participating in all functions provided by the Adviser to the Funds. Laura is responsible for the administration of the fair valuation process to the extent that the Funds have delegated that duty to the Adviser, certain adviser financial and administrative functions and regulatory compliance matters. Laura is also responsible for developing procedures and policies that are reasonably designed to ensure that the Funds operate in accordance with the Funds’ registration statements. Laura graduated with a B.A. from Lafayette College.
Kolotioloma Silue, Manager of Fund Administration
Kolotioloma Silue joined TCM in August 2010. Before joining TCM, Kolotioloma worked as a Business Analyst and Reporting Specialist with JPMorgan Chase & Co. Kolotioloma also worked at Brown Brothers Harriman & Co. as a Mutual Fund Accounting Supervisor from 2001 until 2008. Kolotioloma is responsible for the accuracy and integrity of the Funds’ custody and accounting records and supporting the Chief Compliance Officer in areas such as financial and regulatory reporting and maintaining the system of internal controls. Kolotioloma responsibilities also include assisting the President with projects as assigned. He holds a B.A. degree in Business Economics from the University of Maine.